Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Horowicz-Mehler, Nathalie
26  Ergebnisse:
Personensuche X
?
1

Enzyme replacement therapy treatment patterns and patient o..:

Kurashige, Ian ; Baek, Aiden ; Pichardo, Angel...
Molecular Genetics and Metabolism.  132 (2021)  2 - p. S60-S61 , 2021
Link: https://doi.org/10.1016/..
 
?
2

Impact of Etanercept Therapy on Disease Activity and Health..:

Kotak, Sameer ; Mardekian, Jack ; Horowicz-Mehler, Nathalie...
Value in Health.  18 (2015)  6 - p. 817-823 , 2015
Link: https://doi.org/10.1016/..
 
?
3

How the Biopharmaceutical Industry Can Navigate a Healthcar..:

Doyle, John J. ; Horowicz-Mehler, Nathalie
Pharmaceutical Medicine.  25 (2011)  6 - p. 361-365 , 2011
Link: https://doi.org/10.1007/..
 
?
4

The impact of indirect (herd) protection on the cost-effect..:

Isaacman, Daniel J. ; Strutton, David R. ; Kalpas, Edward A....
Clinical Therapeutics.  30 (2008)  2 - p. 341-357 , 2008
Link: https://doi.org/10.1016/..
 
?
5

Improving Patient and Nurse Outcomes: A Comparison of Nurse..:

Evans, Christopher ; Schein, Jeff ; Nelson, Winnie...
Pain Management Nursing.  8 (2007)  2 - p. 86-95 , 2007
Link: https://doi.org/10.1016/..
 
?
6

Management of opioid side effects in cancer-related and chr..:

McNicol, Ewan ; Horowicz-Mehler, Nathalie ; Fisk, Ruth A...
The Journal of Pain.  4 (2003)  5 - p. 231-256 , 2003
Link: https://doi.org/10.1016/..
 
?
7

Contraceptive and noncontraceptive benefits of the LNG-IUS ..:

Hendlish, Sarah K. ; Horowicz-Mehler, Nathalie C. ; Brixner, Diana I....
Contraception.  78 (2008)  1 - p. 36-41 , 2008
Link: https://doi.org/10.1016/..
 
?
8

Risk for Lung or Liver Metastasis in Women with Metastatic ..:

Horowicz-Mehler, Nathalie Cecilia
https://doi.org/10.7916/D8HD81C6.  , 2017
Link: https://doi.org/10.7916/..
 
?
9

HPR1 Prescription Nutraceutical Clinical Evidence Requireme..:

Orzechowski, AL ; Dahlberg, S ; Cotter, M.T..
Value in Health.  27 (2024)  6 - p. S196 , 2024
Link: https://doi.org/10.1016/..
 
?
10

HPR27 Optimizing Drug Market Exclusivity in the US and EU M..:

Dahlberg, S ; Orzechowski, AL ; Cotter, M.T..
Value in Health.  27 (2024)  6 - p. S200 , 2024
Link: https://doi.org/10.1016/..
 
?
11

Companion Devices: Potential Routes To Market:

Gee, A ; Horowicz-Mehler, N ; Chawla, AS
Value in Health.  18 (2015)  7 - p. A371 , 2015
Link: https://doi.org/10.1016/..
 
?
12

Companion devices: transformative Mobile Health Technology ..:

Chawla, A.S. ; Paul, A. ; Horowicz-Mehler, N...
Value in Health.  18 (2015)  3 - p. A49 , 2015
Link: https://doi.org/10.1016/..
 
?
13

Clinical Practice Of Intrathecal Drugs For Management Of Pa..:

Chawla, A.S. ; Horowicz-Mehler, N. ; Faulkner, E.C...
Value in Health.  17 (2014)  3 - p. A66 , 2014
Link: https://doi.org/10.1016/..
 
?
14

An Analysis Of Real World Data Trends In Global Hta Markets:

Horowicz-Mehler, N. ; Tao, C. ; Faulkner, E.C..
Value in Health.  17 (2014)  3 - p. A28-A29 , 2014
Link: https://doi.org/10.1016/..
 
?
15

The Case For Early Payer Engagement:

Leigh, C. ; Faulkner, E. ; Horowicz-Mehler, N.
Value in Health.  17 (2014)  7 - p. A451 , 2014
Link: https://doi.org/10.1016/..
 
1-15